A Rheumatoid Arthritis (RA) Study Treating Signs and Symptoms of RA in People With RA & Receiving Methotrexate
NCT ID: NCT00038298
Last Updated: 2011-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
53 participants
INTERVENTIONAL
2002-04-30
2004-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Multiple Dose Study to Evaluate Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis
NCT00293826
Long-Term Assessment of Safety and Physical Function With AMG 108 in RA
NCT00369473
Safety and Efficacy of AMG 827 in Subjects With RA
NCT01059448
Evaluation of 2 Oral Doses of PG-760564 in Rheumatoid Arthritis (RA) Patients Receiving Methotrexate
NCT00369928
Brodalumab (AMG 827) in Rheumatoid Arthritis (RA) Participants With Inadequate Response to Methotrexate
NCT00950989
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
50 mg
50 mg 3 times weekly
AMG 719
50 mg 3 times weekly
400 mg
400 mg 3 times weekly
AMG 719
400 mg 3 times weekly
200 mg
200 mg 3 times weekly
AGM 719
200 mg 3 times weekly
Placebo
Placebo comparator associated with each active arm. (3:1 active vs placebo)
Placebo
Placebo given 3 times weekly
placebo to AMG 719
Placebo dose given 3 times weekly
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Placebo given 3 times weekly
AMG 719
50 mg 3 times weekly
AGM 719
200 mg 3 times weekly
AMG 719
400 mg 3 times weekly
placebo to AMG 719
Placebo dose given 3 times weekly
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with Rheumatoid Arthritis, with a disease duration of at least 24 weeks, receiving methotrexate, and having no recent history of substance or alcohol abuse
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amgen Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Related Links
Access external resources that provide additional context or updates about the study.
AmgenTrials clinical trials website
Notice regarding posted summaries of trial results
To access clinical trial results information click on this link
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20010238
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.